Inhibikase Therapeutics, Inc. Proceeds from Notes Payable
Inhibikase Therapeutics, Inc. (IKT) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2022-03-31
- Inhibikase Therapeutics, Inc. proceeds from notes payable for the quarter ending 2021-12-31 was $0.00.
- Inhibikase Therapeutics, Inc. proceeds from notes payable for the quarter ending 2020-12-31 was $0.00.
- Inhibikase Therapeutics, Inc. proceeds from notes payable for the quarter ending 2020-09-30 was $0.00.
- Inhibikase Therapeutics, Inc. proceeds from notes payable for the quarter ending 2020-06-30 was $27.55K.
- Inhibikase Therapeutics, Inc. proceeds from notes payable for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Inhibikase Therapeutics, Inc. proceeds from notes payable for fiscal 2020 was $272.80K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $27.55K derived: sum of 3 quarters · filed 2022-03-31 | $272.80K 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $27.55K derived: sum of 2 quarters · filed 2021-11-15 | $272.80K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $27.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $272.80K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $245.25K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |